The University of Tokyo,  The Institute of Medical Science, Division for AIDS Vaccine Development
National Institute of Infectious Diseases, AIDS Research Center, Groups 1 and 2
 
 

updated on October 4, 2017


• The research article by Dr. Sayuri Seki, Dr. Takushi Nomura, and Dr. Masako Nishizawa was published in PLoS Pathog. (2017.9.21)

Seki, S., Nomura, T., Nishizawa, M., Yamamoto, H., Ishii, H., Matsuoka, S., Shiino, T., Sato, H., Mizuta, K., Sakawaki, H., Miura, T., Naruse, T.K., Kimura, A., and Matano, T. In vivo virulence of MHC-adapted AIDS virus serially-passaged through MHC-mismatched hosts. PLoS Pathog, 13:e1006638, 2017.


• The result of phase I clinical trial using SeV vector (S001) was reported in J. Infect. Dis. (2016.10.17)

Nyombayire, J., Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C.L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J.-L., Fast, P., Laufer, D.S., Cox, J.H., and the S001 Study Team. First-in-human evaluation of the safety and immunogenicity of a replicating intranasally administered Sendai HIV-1 Gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis., 215:95-104. 2017.


• GHIT has announced to award an investment to a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID. (2016.10.5)

This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection. 


    GHIT press room     GHIT web site     VLP Therapeutics web site


• The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations, England, Kenya and Rwanda. The SeV vector AIDS vaccine system has been developed by our research group. (2013.4.2)

 

     Press release from IAVI on September 23, 2013

     Information on this project in IAVI Web















>> AIDS Research Center website

 

Matano Research Group

Welcome to Our Lab!

Contact us

AIDS Research Center
National Institute of Infectious Diseases

1-23-1 Toyama, Shinjuku-ku

Tokyo 162-8640, Japan

Department of AIDS Vaccine Development
The Institute of Medical Science

The University of Tokyo

TEL: 03-5285-1111 (ext. 2302) 

FAX: 03-5285-1165